Immune microenvironment to predict response of cancer chemotherapy and radiotherapy

Immunopharmacogenomics

Volumn , Issue , 2015, Pages 143-155

  Park, Jae Hyun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biomarker; Chemotherapy; Immune microenvironment; Radiotherapy; T lymphocyte; T cell receptor; Tumor immunity

Indexed keywords

EID: 84956492816     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55726-5_9     Document Type: Chapter

References (51)

1. American Society of Clinical Oncology. The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract. 2014;10:119-42.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
3. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643-53.
4. Chabner BA, Roberts TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65-72.
5. Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9:193-9.
6. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-82.
7. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32.
8. Van der Jeught K, Bialkowski L, Daszkiewicz L, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359-81.
9. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours:impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
10. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
12. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol. 2012;2:95.
13. Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;22:113-24.
14. Sakaguchi S,Miyara M, Costantino CM, Hafler DA. FOXP3C regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490-500.
15. Kees T, Egeblad M. Innate immune cells in breast cancer-from villains to heroes? J Mammary Gland Biol Neoplasia. 2011;16:189-203.
16. Hong M, Puaux A-L, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71:6997-7009.
17. Newcomb EW, Demaria S, Lukyanov Y, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res. 2006;12:4730-7.
18. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204:49-55.
19. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med. 2011;236:567-79.
20. Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9, e115103.
21. Yasuda K, Nirei T, Sunami E, et al. Density of CD4(C) and CD8(C) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 2011;6:49.
22. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009;28:105-13.
23. Ladoire S, Arnould L, Mignot G, et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer. 2011;105:366-71.
24. Oda N, Shimazu K, Naoi Y, et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012;136:107-16.
25. Brown JR, Wimberly H, Lannin DR, et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20:5995-6005.
26. Miyashita M, Sasano H, Tamaki K, et al. Tumor-infiltrating CD8C and FOXP3C lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2014;148:525-34.
27. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104:3967-72.
28. Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3C) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo- or chemoimmunotherapy. J Immunother. 2010;33:435-41.
29. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-13.
30. Mahmoud SMA, Paish EC, Powe DG, et al. Tumor-infiltrating CD8C lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949-55.
31. Distel LV, Fickenscher R, Dietel K, et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol. 2009;45:e167-74.
32. Tabachnyk M, Distel LVR, Büttner M, et al. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer. Oral Oncol. 2012;48:594-601.
33. Karakhanova S, Ryschich E, Mosl B, et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 2015;112:1027-36.
34. Liu S, Lachapelle J, Leung S, et al. CD8C lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.
35. Gao Q, Qiu S-J, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-93.
36. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14:5220-7.
37. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678-83.
38. Fukunaga A, Miyamoto M, Cho Y, et al. CD8C tumor-infiltrating lymphocytes together with CD4C tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26-31.
39. Péguillet I, Milder M, Louis D, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16.
40. García-Martínez E, Luengo Gil G, Chaves Benito A, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16:488.
41. Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013;19:28-33.
42. Stoll G, Enot D, Mlecnik B, et al. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology. 2014;3:e27884.
43. Baum PD, Venturi V, Price DA. Wrestling with the repertoire: the promise and perils of next generation sequencing for antigen receptors. Eur J Immunol. 2012;42:2834-9.
44. Fang H, Yamaguchi R, Liu X. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor ' and " chains using next-generation sequencing. OncoImmunology. 2015;3:e968467.
45. Liu X, Venkataraman G, Lin J, et al. Highly clonal T cell receptor repertoire among regulatory T cells in follicular lymphoma tissues: correlation with the CD8C T cell receptor repertoire. OncoImmunology. 2015;4:e1002728.
46. Jang M, Yew PY, Hasegawa K, et al. Characterization of T cell repertoire of blood, tumor and ascites in ovarian cancer patients using next generation sequencing. OncoImmunology. 2015 (in press).
47. Boegel S, Löwer M, Bukur T. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology. 2014;3:e954893.
48. Robbins PF, Lu Y-C, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747-52.
49. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48-61.
50. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51.
51. Victor CT-S, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer. Nature (Lond). 2015;520:373-7.